I am a board-certified medical oncologist who treats people with prostate cancer and other genitourinary cancers. My primary focus is on the medical treatment of men with advanced or high-risk prostate cancer. I have been doing this work for more than a decade.
I also develop and design clinical trials testing new treatments for men with prostate cancer. I have had a leadership role in the development of clinical trials using androgen receptor (AR)-targeted therapies (such as abiraterone, enzalutamide, and apalutamide) for patients with advanced prostate cancer. The survival benefits shown in these trials changed the standard of care for patients with advanced disease. I am now focused on improving outcomes for patients in need of additional treatments by using new AR-directed therapies and combinations of targeted agents.